During the corresponding time, Vanda Pharmaceuticals Inc saw a revenue deteriorated by -3.92 % year on year, sequentially revenue fell by -2.3 %. While revenue at the Vanda Pharmaceuticals Inc 's corporate clients
Vanda Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company markets and sells PONVORY® in the U.S. and Canadian markets for the treatment of relapsing multiple sclerosis (RMS) in adults. PONVORY® received FDA approval in March 2021 and Health Canada approval in April 2021. The product was commercially launched in the U.S. in April 2021 by one of the Johnson & Johnson companies. Additionally, the company markets NEREUS™ in the U.S. for the prevention of vomiting induced by motion sickness in adults; this product was approved in December 2025. Motion sickness affects approximately 30% of the general population under typical travel conditions, including sea, air, and land travel. The company serves patients with multiple sclerosis and adults experiencing motion sickness as specific market segments. Customers and markets referenced include Actelion Pharmaceuticals Ltd. (Janssen) and Johnson & Johnson.
Vanda Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company markets and sells PONVORY® in the U.S. and Canadian markets for the treatment of relapsing multiple sclerosis (RMS) in adults. PONVORY® received FDA approval in March 2021 and Health Canada approval in April 2021. The product was commercially launched in the U.S. in April 2021 by one of the Johnson & Johnson companies. Additionally, the company markets NEREUS™ in the U.S. for the prevention of vomiting induced by motion sickness in adults; this product was approved in December 2025. Motion sickness affects approximately 30% of the general population under typical travel conditions, including sea, air, and land travel. The company serves patients with multiple sclerosis and adults experiencing motion sickness as specific market segments. Customers and markets referenced include Actelion Pharmaceuticals Ltd. (Janssen) and Johnson & Johnson.
Sources:
Vanda Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vanda Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vanda Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
129.73 %